| Sector |
Healthcare
|
Compare with Sector peers |
| Industry |
Pharmaceuticals & Drugs
|
Compare with Industry peers |
| Website | http://www.decanhealthcare.co.in | |
| Financial Indicators | ||
|---|---|---|
| Market Cap | 44.23 Cr. | |
| Earnings per share (EPS) | 0.25 | Trailing Twelve Months Ending 2021-03 |
| Price-Earning Ratio (PE) | 113.42 | Trailing Twelve Months Ending 2021-03 |
| Industry PE | 35.25 | Trailing Twelve Months Ending 2021-03 |
| Book Value / Share | 48.51 | Trailing Twelve Months Ending 2021-03 |
| Price to Book Value | 0.58 | Calculated using Price: 28.15 |
| Dividend Yield | 0.00 | Period Ending 2020-03 |
| No. of Shares Subscribed | 1.57 Cr. | 15,713,430 Shares |
| FaceValue | 10 | |
| Company Profile | ||
|
The Company was originally incorporated as Deccan Health Care Limited at Hyderabad, Andhra Pradesh as a Public Limited Company under the provision of Companies Act, 1956 vide Certificate of Incorporation dated June 14, 1996 issued by the Registrar of Companies, Andhra Pradesh, Hyderabad. Subsequently, the Company was converted into a private limited company and the name of the Company was changed to Deccan Health Care Private Limited vide a Fresh Certificate of Incorporation dated June 12, 2009, issued by the Assistant Registrar of Companies, Andhra Pradesh. Further, the Company was converted into a public limited company pursuant to special resolution passed by the members in Extraordinary General Meeting held on August 12, 2017 and the name of the Company was changed to Deccan Health Care Limited vide a Fresh Certificate of Incorporation dated August 31, 2017, issued by the Registrar of Companies, Andhra Pradesh, Hyderabad. Business area of the Company: The Company is engaged in developing, manufacturing and marketing a broad range of healthcare products including nutraceutical, cosmeceutical and ayurveda products. In the present competitive era of medicines and food supplements, it aims to distinguish its identity by focusing on ways to bridge the nutrition gap which is a recognised cause of many diseases. It mainly develops and market differentiated healthcare products specializing in nutraceutical and cosmeceutical products, which it commercialize through different revenue channels that takes the products solutions to the consumers which includes network of distributors, marketing agents, direct to consumers and e-commerce channel for its domestic sales. The Company offers more than 1500 products. These products are used for various purposes such as hair care, skin care, heart care, immunity building etc. The Company offers a long-chain omerga-3 fatty acid, joint health nutrients, diacerein, antioxidants, immune enhancing components, skin ageing products, instant energy drinks, and calcium supplements; and a formula for males. The Company supplies their products in various forms such as tablets, capsules, gel, liquids, ointments, powder, pastes, etc. Major Events and Milestones:
Key Awards, Certifications, Accreditations and Recognitions:
|
||
Company Profile
The Company was originally incorporated as Deccan Health Care Limited at Hyderabad, Andhra Pradesh as a Public Limited Company under the provision of Companies Act, 1956 vide Certificate of Incorporation dated June 14, 1996 issued by the Registrar of Companies, Andhra Pradesh, Hyderabad. Subsequently, the Company was converted into a private limited company and the name of the Company was changed to Deccan Health Care Private Limited vide a Fresh Certificate of Incorporation dated June 12, 2009, issued by the Assistant Registrar of Companies, Andhra Pradesh. Further, the Company was converted into a public limited company pursuant to special resolution passed by the members in Extraordinary General Meeting held on August 12, 2017 and the name of the Company was changed to Deccan Health Care Limited vide a Fresh Certificate of Incorporation dated August 31, 2017, issued by the Registrar of Companies, Andhra Pradesh, Hyderabad.
Business area of the Company:
The Company is engaged in developing, manufacturing and marketing a broad range of healthcare products including nutraceutical, cosmeceutical and ayurveda products. In the present competitive era of medicines and food supplements, it aims to distinguish its identity by focusing on ways to bridge the nutrition gap which is a recognised cause of many diseases. It mainly develops and market differentiated healthcare products specializing in nutraceutical and cosmeceutical products, which it commercialize through different revenue channels that takes the products solutions to the consumers which includes network of distributors, marketing agents, direct to consumers and e-commerce channel for its domestic sales. The Company offers more than 1500 products. These products are used for various purposes such as hair care, skin care, heart care, immunity building etc. The Company offers a long-chain omerga-3 fatty acid, joint health nutrients, diacerein, antioxidants, immune enhancing components, skin ageing products, instant energy drinks, and calcium supplements; and a formula for males. The Company supplies their products in various forms such as tablets, capsules, gel, liquids, ointments, powder, pastes, etc.
Major Events and Milestones:
Key Awards, Certifications, Accreditations and Recognitions:
| 1 Day |
|
+1.24% |
| 1 Week |
|
+5.56% |
| 1 Month |
|
-6.86% |
| 3 Month |
|
-10.80% |
| 6 Month |
|
+9.83% |
| 1 Year |
|
-25.00% |
| 2 Year |
|
-65.16% |
| 5 Year |
|
| 9 years | 2012-03 | 2013-03 | 2014-03 | 2015-03 | 2016-03 | 2017-03 | 2018-03 | 2019-03 | 2020-03 | |
| Return on Equity (%) | -59.17 | -38.15 | -47.88 | -17.65 | 41.69 | 48.74 | 39.11 | 25.78 | 14.17 | |
| Return on Capital Employed (%) | -28.74 | -14.86 | -14.16 | 1.30 | 22.50 | 35.84 | 32.92 | 25.04 | 14.22 | |
| Return on Assets (%) | -28.82 | -16.02 | -14.86 | -4.31 | 14.33 | 21.67 | 22.25 | 18.89 | 11.47 |
| Particulars | 9 years | 2012-03 Rs. Cr. | 2013-03 Rs. Cr. | 2014-03 Rs. Cr. | 2015-03 Rs. Cr. | 2016-03 Rs. Cr. | 2017-03 Rs. Cr. | 2018-03 Rs. Cr. | 2019-03 Rs. Cr. | 2020-03 Rs. Cr. |
| Shh. Funds | 26 | 19 | 14 | 12 | 17 | 22 | 46 | 66 | 76 | |
| Non Curr. Liab. | 11 | 11 | 13 | 16 | 17 | 13 | 11 | 3 | 3 | |
| Curr. Liab. | 5 | 10 | 6 | 4 | 4 | 15 | 14 | 14 | 14 | |
| Minority Int. | ||||||||||
| Equity & Liab. | 42 | 40 | 33 | 32 | 38 | 50 | 70 | 83 | 93 | |
| Non Curr. Assets | 22 | 21 | 19 | 18 | 17 | 19 | 32 | 26 | 27 | |
| Curr. Assets | 20 | 20 | 14 | 14 | 21 | 31 | 39 | 57 | 66 | |
| Misc. Exp. not W/O | 0 | 0 | 0 | 0 | ||||||
| Total Assets | 42 | 40 | 33 | 32 | 38 | 50 | 70 | 83 | 93 |
| Particulars | 9 years | 2012-03 Rs. Cr. | 2013-03 Rs. Cr. | 2014-03 Rs. Cr. | 2015-03 Rs. Cr. | 2016-03 Rs. Cr. | 2017-03 Rs. Cr. | 2018-03 Rs. Cr. | 2019-03 Rs. Cr. | 2020-03 Rs. Cr. |
| Net Sales | 8 | 9 | 7 | 9 | 13 | 29 | 38 | 44 | 42 | |
| Other Income | 1 | 0 | 0 | 0 | 4 | 0 | 2 | 0 | 0 | |
| Total Income | 9 | 9 | 7 | 9 | 17 | 29 | 40 | 44 | 42 | |
| Total Expenditure | -18 | -13 | -10 | -7 | -9 | -17 | -24 | -27 | -31 | |
| PBIDT | -9 | -4 | -3 | 2 | 8 | 13 | 16 | 17 | 12 | |
| Interest | -2 | -1 | -2 | -2 | -1 | -2 | -2 | -1 | 0 | |
| Depreciation | -1 | -1 | -1 | -1 | -1 | -1 | -1 | -1 | -1 | |
| Taxation | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |
| Exceptional Items | 0 | 0 | ||||||||
| PAT | -12 | -7 | -5 | -1 | 5 | 10 | 13 | 14 | 10 |
| Particulars | 9 years | 2012-03 Rs. Cr. | 2013-03 Rs. Cr. | 2014-03 Rs. Cr. | 2015-03 Rs. Cr. | 2016-03 Rs. Cr. | 2017-03 Rs. Cr. | 2018-03 Rs. Cr. | 2019-03 Rs. Cr. | 2020-03 Rs. Cr. |
| Cash Fr. Operatn. | -3 | 1 | 0 | -1 | 2 | 13 | 3 | 1 | ||
| Cash Fr. Inv. | 0 | 0 | 0 | -1 | -13 | -12 | -2 | |||
| Cash Fr. Finan. | 3 | -2 | 0 | 1 | -1 | 0 | 13 | 0 | ||
| Net Change | 0 | 0 | 0 | 0 | 0 | 0 | 4 | -1 | ||
| Cash & Cash Eqvt | 0 | 0 | 0 | 0 | 0 | 0 | 4 | 3 |
|
Wed, 21 Jul 2021
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018 Pursuant to compliance of Regulation 74(5) of the SEBI (Depositaries and Participants) Regulation 20l8 Compliance Certificate for non-applicability for the quarter ended 30th June 2021 |
||||||||||||||
|
Thu, 15 Jul 2021
Statement Of Investor Complaints For The Quarter Ended June 2021
|
||||||||||||||
|
Wed, 14 Jul 2021
Announcement under Regulation 30 (LODR)-Meeting Updates Deccan Health Care Limited FY 21 Results supplementary information |
| Mon, 26 Jul 2021 |
Stock Underperforming Benchmark Index in both 1 Week and 3 Month
|
Stock Underperforming Sectoral Index in both 1 Week and 3 Month
|
Strongly Underperforming Benchmark index
|
Strongly Underperforming Sectoral index
|
Both SRS And ARS Below Zero
|
Equities
M.F.
Sectors